Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
31/07/26	CA$0.4000	+2.56%	33,500
30/07/26	CA$0.3900	-2.50%	12,020
29/07/26	CA$0.4000	-4.76%	7,099
28/07/26	CA$0.4200	+5.00%	53,606
27/07/26	CA$0.4000	+6.67%	76,066

Delayed Quote Canadian Securities Exchange

More quotes

Income Statement and Estimates

More financial data

Delayed Canadian Securities Exchange Other stock markets 23:57:50 31/07/2026 +04			5-day change	1st Jan Change
0.4000 ^CAD	-.--%		+6.67%	-44.44%

07-08	Defence Therapeutics Opens New Office In Hamilton To Expand Its Accum Radiopharmaceutical Platform	CI
06-03	Defence Therapeutics Inc. Announces Appointment of John Beaver to Its Board of Director	CI

Market Cap	33.35M 23.74M 20.63M 19.26M 17.69M 2.26B 33.93M 227M 88.97M 1.13B 89.18M 87.21M 3.72B	P/E 2024	-2.5x	P/E 2025	-9.9x
Enterprise Value	33.62M 23.94M 20.8M 19.42M 17.83M 2.28B 34.2M 229M 89.69M 1.14B 89.91M 87.92M 3.75B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	66.13%	Yield 2024 *	-	Yield 2025	-

07-08	Defence Therapeutics Opens New Office In Hamilton To Expand Its Accum Radiopharmaceutical Platform	CI
06-03	Defence Therapeutics Inc. Announces Appointment of John Beaver to Its Board of Director	CI
06-01	Defence Therapeutics Inc. Appoints Dr. John Lambert as Board Director, Effective 1 June 2026	CI
05-30	Defence Therapeutics Inc. Announces Resignation of Dr. Sarkis Meterissian from Board, Joins Scientific Advisory Board	CI
05-23	Defence Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-19	Defence Therapeutics Inc Expands In-House Adc Development Platform with Enhanced Analytical and Cellular Testing Capabilities	CI
03-06	Defence Therapeutics Inc. announced that it has received CAD 9.595 million in funding	CI
02-27	Defence Therapeutics Inc. announced that it expects to receive CAD 11 million in funding	CI
02-21	Defence Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
01-28	Defence Therapeutics Expands Collaboration With Canadian Nuclear Laboratories	MT
01-28	Defence Therapeutics Inc. Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline	CI
12-04	Defence Therapeutics Inc. Announces the Formation of Its Inaugural Scientific Advisory Board	CI
11-28	Defence Therapeutics Inc. Reports Earnings Results for the First Quarter Ended September 30, 2025	CI

07-08	Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform	NE
07-07	Defence Therapeutics : Opens New Office In Hamilton To Expand Its Accum Radiopharmaceutical Platform	PU
06-17	Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions	NE
06-03	Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors	NE
06-01	Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors	NE

Defence Therapeutics Inc. Stock

Stocks

DTC

CA24463V1013

Biotechnology & Medical Research

Valuation: Defence Therapeutics Inc.

Chart: Defence Therapeutics Inc.

Latest news : Defence Therapeutics Inc.

Press Releases: Defence Therapeutics Inc.

News in other languages: Defence Therapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Defence Therapeutics Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

19/08/24	DEFENCE UNTERSUCHT DIE ANWENDUNG DER ACCUM®- HYDROGELTECHNOLOGIE ZUM TRANSPORT VON GLP-1 ZWECKS VERBESSERUNG DER WIRKSAMKEIT DER BEHANDLUNG VON DIABETES UND ZUM ERZIELEN EINES GEWICHTSVERLUSTS
13/08/24	KOOPERATIONSVEREINBARUNG VON DEFENCE THERAPEUTICS MIT ORANO ZUR ENTWICKLUNG DER NÄCHSTEN GENERATION DER GEZIELTEN RADIOIMMUNTHERAPIE FÜR FORTSCHRITTE BEI DER KREBSBEKÄMPFUNG
24/07/24	DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES ZUR BESCHLEUNIGUNG DER ENTWICKLUNG SEINES RADIOIMMUNOKONJUGAT-PROGRAMMS
08/07/24	DEFENCE ERHÄLT ‚NO OBJECTION LETTER’ VON DER KANADISCHEN GESUNDHEITSBEHÖRDE HEALTH CANADA FÜR SEINE PHASE I-STUDIE MIT ACCUM-002 (ACCUTOX) ALS MOLEKÜL ZUR KREBSBEKÄMPFUNG BEI PATIENTEN MIT MELANOMEN
01/07/24	ACCUTOX VON DEFENCE VERSTÄRKT DIE WIRKUNG VON IMMUNCHECKPOINTINHIBITOREN UND SCHAFFT SO SYNERGIEEFFEKTE

1 week	+6.67%
1 month	-8.05%
3 months	-32.20%
6 months	-34.43%
Current year	-44.44%

1 week	0.38	0.42
1 month	0.36	0.5
Current year	0.36	0.74
1 year	0.36	0.93
3 years	0.36	3.04
5 years	0.36	8.15
10 years	0.36	8.15

Manager	Title	Age	Since
Sébastien Plouffe CEO	Chief Executive Officer	53	27/09/2024
Arnab De DFI	Director of Finance/CFO	55	20/12/2024
Maxime Parisotto CTO	Chief Tech/Sci/R&D Officer	-	25/11/2024

Director	Title	Age	Since
Sébastien Plouffe BRD	Director/Board Member	53	02/06/2020
Sarkis Meterissian BRD	Director/Board Member	64	05/01/2021
Philippe Lefrancois BRD	Director/Board Member	-	27/09/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/12/25	Svetlana Selivanova	Option	Director	50,000	0.0914%
16/12/25	Amie Phinney	Other	Director	0	0%
16/12/25	Amie Phinney	Option	Director	50,000	0.0914%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DEFENCE THERAPEUTICS INC.	-.--%	+6.67%	-34.43%	-85.71%	21.61M
LONZA GROUP AG	-0.36%	+0.14%	-0.95%	+14.33%	48.53B
REVOLUTION MEDICINES, INC.	-2.78%	-2.45%	+393.44%	+475.29%	39.87B
IQVIA HOLDINGS INC.	-0.88%	+8.86%	+27.01%	+7.31%	38.68B
BEONE MEDICINES AG	-1.53%	-4.66%	+2.11%	+50.96%	35.13B
CELLTRION, INC.	-2.41%	+2.59%	+11.68%	+41.16%	29.79B
MEDPACE HOLDINGS, INC.	+0.16%	-2.65%	+32.67%	+122.34%	16.11B
ASCENDIS PHARMA A/S	+0.43%	-4.11%	-	-	16.08B
EUROFINS SCIENTIFIC SE	-0.62%	+1.23%	+1.80%	+15.05%	13.61B
ICON PUBLIC LIMITED COMPANY	-2.50%	-7.17%	-4.93%	-37.59%	12.62B
Average	-1.21%	+1.44%	+47.60%	+67.01%	25.04B
Weighted average by Cap.	-1.26%	+1.82%	+75.07%	+105.15%

	2024	2025
Net sales	-	-
Net income	-13.19M -9.39M -8.16M -7.62M -7M -895M -13.42M -89.87M -35.2M -446M -35.28M -34.5M -1.47B	-3.52M -2.51M -2.18M -2.03M -1.87M -239M -3.58M -23.99M -9.4M -119M -9.42M -9.21M -393M
Net Debt	1.69M 1.2M 1.05M 976K 896K 115M 1.72M 11.51M 4.51M 57.19M 4.52M 4.42M 189M	272K 194K 168K 157K 144K 18.45M 277K 1.85M 725K 9.2M 727K 711K 30.34M